Bee venom immunotherapy induces a shift in cytokine responses from a TH‐2 to a TH‐1 dominant pattern: comparison of rush and conventional immunotherapy
- 1 September 1995
- journal article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 25 (9) , 828-838
- https://doi.org/10.1111/j.1365-2222.1995.tb00025.x
Abstract
Background: The mechanism of immunotherapy is unclear. Allergic disease is known to involve enhanced TH-2 cytokine responses to allergen. Objective: In order to investigate the mechanisms of immunotherapy, we have examined changes in cytokine secretion before (13 patients) and during (nine patients) both rush and conventional venom immunotherapy (VIT) in nee venom allergic patient. Method Peripheral blood mononuclear cells were stimulated in vitro with see venom, non-specific antigen or mitogen and secretion of IL-4 (TH-2) and IFNγ (TH-1) over the culture period measured. Results: Untreated patients had TH-2 responses to venom and TH-1 responses to antigen and strong proliferative responses to venom. Controls showed no response (proliferation or cytokines) to venom and the normal TH-1 response to antigen. VIT resulted in marked changes in cytokine secretion to venom, with reduction of the abnormal TH-2 response and induction of a TH-1 response. The pattern differed in rush and conventional VIT. One day after rush VIT there was a significant fall in IL-4 secretion (P < 0.01), which rose by 3 weeks then declined. In conventional ViT there was a gradual reduction of IL-4 production significant after 2 months and undetectable by 6 months. IFNγ secretion was induced by VIT. Proliferative responses mirrored the IL-4 changes. One day after rush VIT there was a loss of T cells, monocytes and NK cells from peripheral blood. Conclusion: This study shows that immmotherapy shifted cytokine responses to allergen from a TH-2 to a TH-1 dominant pattern, suggesting direct effects on T cells. How these cytokine changes relate to clinical desensitization is not clear. In the longer term they would result in an isotype switch from IgE to IgG. Early changes in cytokine or chemokine production might down regulate mast cell or basophil reactivity and explain the rapid desensilization in rush VIT.Keywords
This publication has 37 references indexed in Scilit:
- Human TH1 and TH2 subsets: doubt no morePublished by Elsevier ,2004
- Activation-Driven Death of Human T Cell Clones: Time Course Kinetics of the Induction of Cell Shrinkage, DNA Fragmentation, and Cell DeathCellular Immunology, 1993
- Peripheral blood mononuclear cells from house dust mite allergic patients produce IL‐2 in response to specific allergen challengeClinical and Experimental Allergy, 1993
- Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils.The Journal of Experimental Medicine, 1992
- IL-3 Primes and Evokes Histamine Release from Human Basophils but not Mast CellsInternational Archives of Allergy and Immunology, 1992
- 658 Immunohistology of allergen-induced late nasal responsesJournal of Allergy and Clinical Immunology, 1991
- A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclassesJournal of Allergy and Clinical Immunology, 1990
- Provocation test with a living insect as a diagnostic tool in systemic reactions to bee and wasp venom: a prospective study with emphasis on the clinical aspectsClinical and Experimental Allergy, 1987
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986